65,437 trials
HIV-1-infection
Primary: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 0.4; 1.1 percentage of participants — p=0.37
Hypertension
Primary: Change From Baseline in Clinic Systolic Blood Pressure (SBP) at Month 6 — 156.8; -30.5 mmHg — p=<0.001
Advanced Refractory Left Ventricular Heart Failure
Primary: Short Term Primary End Point — 109; 131 Participants — p=<0.001
Asthma
Primary: Serum Prednisolone Levels Over 24 Hours — 800; 700; NA nmol/l
Prostate Cancer
Primary: Time to Progression — 1.5; 3.3 months
Autoimmune Hepatitis
Primary: Safety/Tolerability Measured by Clinical Laboratory Tests, Metabolics, Cytokines, Anti-PIF Antibody, Periodic Physical Examination, Including Vital Signs Measurements…
Larynx · Lip · Oral Cavity
Primary: Cytokine/Chemokine Profile
Language Development · Literacy
Primary: Bayley Scales of Infant and Toddler Development (Infant is 12-18 Months Old) — 98.8; 99.6; 89.7; 85.7 score on a scale — p=.7635
Renal Transplant Donor of Left Kidney · Donor Nephrectomy · Robotic Surgery
Primary: Successful Completion of the Surgical Procedure — 3 Participants
HIV
Primary: Drug Levels in Blood — 1732 ng/ml
Diabetes Mellitus
Primary: Number of Participant Developed the Skin Inflammation — 0; 0; 0 Participants
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus — 8.2; 7.1 Months — p=0.00894
Schistosomiasis
Primary: Number of Participants With Clinical Cure Determined by Kato-Katz Method — 51; 43; 47; 46 Participants
Diabetes Type 1
Primary: Optimal Time Shift of Continuous Glucose Monitoring Measurements — 1.01 Percentage point change in MARD
Epilepsy
Primary: Functional Connectivity